Breaking News Instant updates and real-time market news.

KMB

Kimberly-Clark

$133.74

0.48 (0.36%)

05:48
03/21/17
03/21
05:48
03/21/17
05:48

Kimberly-Clark initiated with a Neutral at JPMorgan

JPMorgan analyst Andrea Teixeira started Kimberly-Clark with a Neutral rating and $139 price target.

  • 21

    Mar

KMB Kimberly-Clark
$133.74

0.48 (0.36%)

03/10/17
03/10/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Dollar General (DG) downgraded to Neutral from Buy at Buckingham with the firm's analyst saying the environment has become more difficult since the bullish analyst day last spring. The firm's analyst said shares do not appear to fully factor in sales and margin challenges and sees risk to Street expectations. 2. MEDNAX (MD) downgraded to Neutral from Overweight at JPMorgan with analyst Gary Taylor citing valuation following the recent rally in the shares. The analyst says he can't with confidence bump up his $69 price target given the multi-year slowdown of organic growth and its high Medicaid payor exposure. 3. Loxo Oncology (LOXO) downgraded to Neutral from Buy at Citi with analyst Yigal Nochomovitz saying the stock is now fairly valued. The reflect the equity financing in January which expanded the share count and rising R&D spend, the analyst cut his price target for the shares to $45 from $49. He believes, however, that Loxo management is executing the business plan well. 4. Kimberly-Clark (KMB) downgraded to Hold on competition, valuation at Societe Generale with analyst Iain Simpson saying price competition in the U.S. has picked up as P&G is becoming more aggressive with its mid-tier Luvs and competition in Brazil and China remains "tough." The analyst expects cost cutting to drive margins and views cash returns as "robust," but said valuation has caught up with fundamentals. 5. Ionis Pharmaceuticals (IONS) downgraded to Sell from Neutral at Goldman with analyst Salveen Richter saying Ionis has a "lackluster" track record of developing successful drugs and ongoing toxicity across multiple drugs. If volanesorsen is approved for FCS, Richter expects safety/compliance issues and the launch focus on specialists will result in limited returns, similar to drug Kynamro for high cholesterol. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/10/17
SOCG
03/10/17
DOWNGRADE
Target $144
SOCG
Hold
Kimberly-Clark downgraded to Hold on competition, valuation at Societe Generale
Societe Generale analyst Iain Simpson downgraded Kimberly-Clark to Hold from Buy and raised his target price to $144 from $139. Simpson said price competition in the US has picked up as P&G is becoming more aggressive with its mid-tier Luvs and competition in Brazil and China remains "tough." The analyst expects cost cutting to drive margins and views cash returns as "robust," but said valuation has caught up with fundamentals.
02/17/17
RBCM
02/17/17
NO CHANGE
Target $105
RBCM
Outperform
Edgewell Personal Care remains takeout target, says RBC Capital
After Kraft Heinz (KHC) confirmed it had approached Unilever (UN, UL) with a merger proposal, RBC Capital analyst Nik Modi says the news come as a surprise, but does not warrant a change in his Edgewell Personal Care (EPC) takeout thesis. The analyst reiterates an Outperform rating on the latter's shares, with a $105 price target, on improving margin and revenue profile and the prospects of a takeout in the next 12-16 months, with Unilever as one of the more likely buyers. Other potential suitors include Kimberly-Clark (KMB), Beiersdorf, Henkel, Johnson & Johnson (JNJ), Colgate-Palmolive (CL), Church & Dwight (CHD), L'Oreal (LRLCY), and Kao, he adds.
01/09/17
LEHM
01/09/17
DOWNGRADE
Target $109
LEHM
Equal Weight
Kimberly-Clark downgraded to Equal Weight from Overweight at Barclays
Barclays analyst Lauren Lieberman downgraded Kimberly-Clark to Equal Weight after lowering her U.S. Non-Food Consumer Staples sector view to Neutral from Positive. The analyst lowered her price target for the shares to $109 from $125. The analyst sees a less favorable macroeconomic backdrop in 2017 and has "fairly muted expectations" for company fundamentals in the space.

TODAY'S FREE FLY STORIES

MRK

Merck

$64.16

0.375 (0.59%)

11:25
05/22/17
05/22
11:25
05/22/17
11:25
Hot Stocks
Merck says Phase 2 study results warrant continued evaluation of MK-7264 »

Merck announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 27

    May

  • 31

    May

  • 02

    Jun

  • 05

    Jun

  • 09

    Jun

  • 14

    Jun

LC

LendingClub

$5.92

0.26 (4.59%)

, ONDK

On Deck Capital

$3.71

0.32 (9.44%)

11:23
05/22/17
05/22
11:23
05/22/17
11:23
Periodicals
Online lendeers attract bond buyers, WSJ says »

According to…

LC

LendingClub

$5.92

0.26 (4.59%)

ONDK

On Deck Capital

$3.71

0.32 (9.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 27

    Jun

  • 28

    Jun

  • 29

    Jun

MGM

MGM Resorts

$31.66

0.41 (1.31%)

11:20
05/22/17
05/22
11:20
05/22/17
11:20
Options
Notable option blocks in MGM »

Notable option blocks in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

11:17
05/22/17
05/22
11:17
05/22/17
11:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

11:16
05/22/17
05/22
11:16
05/22/17
11:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MTBC

Medical Transcription Billing

$1.90

0.02 (1.06%)

11:15
05/22/17
05/22
11:15
05/22/17
11:15
Hot Stocks
MTBC jumps after announcing releases of app for smartphones »

Earlier today, MTBC…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:15
05/22/17
05/22
11:15
05/22/17
11:15
General news
Breaking General news story  »

3-Month Bill Auction to…

11:15
05/22/17
05/22
11:15
05/22/17
11:15
General news
Breaking General news story  »

6-Month Bill Auction to…

XOM

Exxon Mobil

$82.08

0.147 (0.18%)

11:13
05/22/17
05/22
11:13
05/22/17
11:13
Hot Stocks
Exxon Mobil completes polyethylene lines at Texas plant »

ExxonMobil Chemical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

XOP

SPDR Oil Exploration and Production Fund

$35.37

-0.15 (-0.42%)

11:10
05/22/17
05/22
11:10
05/22/17
11:10
Options
Upside call buying in SPDR Oil Exploration and Production ETF »

Upside call buying in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:10
05/22/17
05/22
11:10
05/22/17
11:10
General news
Treasury announced a $55 B 4-week bill auction for Tuesday »

Treasury announced a $55…

ORBK

Orbotech

$36.72

0.35 (0.96%)

11:09
05/22/17
05/22
11:09
05/22/17
11:09
Hot Stocks
Orbotech sinks after disclosing criminal probe by Israel Tax Authority »

Orbotech earlier today…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 24

    May

AVY

Avery Dennison

$83.18

0.42 (0.51%)

11:09
05/22/17
05/22
11:09
05/22/17
11:09
Hot Stocks
Avery Dennison acquires Finesse Medical »

Avery Dennison…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ORBK

Orbotech

$36.72

0.35 (0.96%)

11:08
05/22/17
05/22
11:08
05/22/17
11:08
Downgrade
Orbotech rating change  »

Orbotech downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 24

    May

RPT

Ramco-Gershenson

$12.75

-0.16 (-1.24%)

11:08
05/22/17
05/22
11:08
05/22/17
11:08
Conference/Events
Ramco-Gershenson management to meet with Jefferies »

Meeting to be held in Las…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

AVT

Avnet

$36.98

-0.1099 (-0.30%)

11:06
05/22/17
05/22
11:06
05/22/17
11:06
Hot Stocks
Avnet named exclusive global distributor for Silego Technology »

Avnet and Silego…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:05
05/22/17
05/22
11:05
05/22/17
11:05
General news
4-Week Bill Announcement Offering Amount data reported »

4-Week Bill Announcement…

RARX

RA Pharmaceuticals

$24.62

-0.32 (-1.28%)

11:04
05/22/17
05/22
11:04
05/22/17
11:04
Conference/Events
RA Pharmaceuticals management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 23

    May

  • 24

    May

  • 25

    May

  • 22

    Jun

BBRY

BlackBerry

$10.38

0.27 (2.67%)

11:00
05/22/17
05/22
11:00
05/22/17
11:00
Options
Blackberry calls active as the rally continues »

Blackberry calls active…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Jun

QUOT

Quotient Technology

$11.30

0.05 (0.44%)

10:58
05/22/17
05/22
10:58
05/22/17
10:58
Conference/Events
Quotient Technology management to meet with Maxim »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 24

    May

QUOT

Quotient Technology

$11.30

0.05 (0.44%)

10:57
05/22/17
05/22
10:57
05/22/17
10:57
Conference/Events
Quotient Technology management to meet with Loop »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 24

    May

RHHBY

Roche

$34.30

0.495 (1.46%)

10:57
05/22/17
05/22
10:57
05/22/17
10:57
Hot Stocks
FDA approves Roche's Actemra for giant cell arteritis »

Genentech, a member of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 06

    Jun

  • 26

    Jun

PQ

PetroQuest

$2.42

0.1285 (5.61%)

10:56
05/22/17
05/22
10:56
05/22/17
10:56
Conference/Events
PetroQuest management to meet with Roth Capital »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 24

    May

  • 25

    May

C

Citi

$60.95

-0.15 (-0.25%)

10:53
05/22/17
05/22
10:53
05/22/17
10:53
Hot Stocks
Citi releases statement on settlement with DOJ over BUSA »

Citi issued the following…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

  • 25

    Jul

PLNT

Planet Fitness

$20.81

0.13 (0.63%)

10:51
05/22/17
05/22
10:51
05/22/17
10:51
Conference/Events
Planet Fitness management to meet with William Blair »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 24

    May

  • 20

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.